1 June

Kidney Int http://www.kidney-international.org/

• 00:00
  Table of Contents Kidney Int
  (Kidney International 101, 6 (2022))
• 00:00
  Subscription Information Kidney Int
  (Kidney International 101, 6 (2022))
• 00:00
  Editorial Board Kidney Int
  (Kidney International 101, 6 (2022))
• 00:00
  In this issue Kidney Int
  In this issue of Kidney International, we are pleased to introduce a new article series called Next Generation Clinical Pathologic Conference (CPC). These articles will merge the traditional CPC with molecular medicine for a fresh approach to decipher mechanisms of kidney disease. In (...) (Kidney International 101, 6 (2022))
• 00:00
  JournalClub Kidney Int
  Rurik et al. (Science. 2022;375:91–96.) (Kidney International 101, 6 (2022))
• 00:00
  Should we consider calcimimetics as a therapeutic option for nephrotic syndrome? - Olivia Lenoir, Pierre-Louis Tharaux Kidney Int
  Calcimimetics allosterically increase the calcium ion sensitivity of the calcium-sensing receptor (CaSR). Using a CaSR knockdown in podocytes and a podocyte-specific CaSR knockout in mice, Mühlig et al. uncovered a stabilizing role for actin cytoskeleton and cell adhesion. Short-term alleviation (...) (Kidney International 101, 6 (2022))
• 00:00
  Renoprotection by GDF15 and Klotho: birds of a feather flock together - Hirotaka Komaba Kidney Int
  Growth differentiation factor 15 is a potential renoprotective factor whose expression is induced primarily at the proximal tubular site after kidney injury. Valiño-Rivas et al. confirmed the protective effect of growth differentiation factor 15 against different types of kidney injury and (...) (Kidney International 101, 6 (2022))
• 00:00
  The authors reply - Johannes F.E. Mann, Alfred K. Cheung Kidney Int
  We thank Subbiah and Bhowmik1 for their comments. They point out that the Kidney Disease: Improving Global Outcomes recommendation2 focuses on the chronic kidney disease (CKD) subgroup of Systolic Blood Pressure Intervention Trial (SPRINT). That is because it is the best available evidence for (...) (Kidney International 101, 6 (2022))
• 00:00
  KDIGO recommendations on blood pressure management in chronic kidney disease - Arunkumar Subbiah, Dipankar Bhowmik Kidney Int
  The “KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease” recommends a systolic blood pressure (BP) target (Kidney International 101, 6 (2022))
• 00:00
  Corrigendum to Fang Y, Chen B, Gong AY, et al. “The ketone body ?-hydroxybutyrate mitigates the senescence response of glomerular podocytes to diabetic insults.” Kidney Int. 2021;100:1037–1053 Kidney Int
  The above-stated article contained an incorrect version of Figure 3 in which the representative micrograph of senescence-associated beta-galactosidase (SA-?-gal) staining in the ?-hydroxybutyrate (?-HB) group in Figure 3a was inadvertently used from the results of a different experiment (...) (Kidney International 101, 6 (2022))
• 00:00
  Corrigendum to Gleeson S, Lightstone L. “BLISS-LN trial revisited: function matters.” Kidney Int. 2022;101:224–226 Kidney Int
  There are 3 corrections for the above-stated article. (Kidney International 101, 6 (2022))
• 00:00
  Acute tubulointerstitial nephritis revealing VEXAS syndrome - Charles Ronsin, Laurent Benard, Amélie Mourtada, François Perrin, Zakaria Boukerroucha Kidney Int
  A new inflammatory disease characterized by somatic X-linked mutation of the UBA1 gene has been recently described in males and named “VEXAS syndrome,” an acronym for “Vacuoles, E1 enzyme, X linked, Autoinflammatory, Somatic syndrome.”1 Despite the fact that it affects the kidneys in up to 10% of (...) (Kidney International 101, 6 (2022))
• 00:00
  Eculizumab impairs killing of Neisseria meningitidis serogroup B in atypical hemolytic uremic syndrome patients vaccinated with MenB-4C - Bryan van den Broek, Michiel van der Flier, Nicole C.A.J. van de Kar, Jack F.M. Wetzels, Marien I. de Jonge, Ronald de Groot, Kioa L. Wijnsma, Jeroen D. Langereis Kidney Int
  Recent reports suggest that eculizumab may not only compromise MenB-4C vaccination–induced serum killing of meningococci, but also opsonophagocytic killing.1,2 Using pre- and postvaccination serum from 5 patients with atypical hemolytic uremic syndrome (aHUS) on treatment with eculizumab and 2 (...) (Kidney International 101, 6 (2022))
• 00:00
  Management of refractory lupus nephritis: rationale to consider tacrolimus - Durga Prasanna Misra, Vikas Agarwal Kidney Int
  We read with great interest the review article by Mejia-Vilet et al. about the management of lupus nephritis (LN).1 The authors mentioned that few uncontrolled studies had evaluated tacrolimus in combination with mycophenolate mofetil for LN.1 In a recent prospective observational study from (...) (Kidney International 101, 6 (2022))
• 00:00
  Protective mechanisms harnessing against injurious heme and preventing kidney damage in STEC-HUS: toward new therapies? - Frank A.D.T.G. Wagener, Nicole C.A.J. van de Kar, Lambert P. van den Heuvel Kidney Int
  Hemolytic uremic syndrome can be initiated by Escherichia coli infections (Shiga-toxin–producing enterohemorrhagic Escherichia coli hemolytic uremic syndrome). When hemoglobin and heme released from ruptured erythrocytes interact with the kidney cells, this can result in platelet activation, (...) (Kidney International 101, 6 (2022))
• 00:00
  The authors reply: - Robyn G. Langham, Ekamol Tantisattamo, Kamyar Kalantar-Zadeh, Siu-Fai Lui Kidney Int
  We appreciate Meyers for sharing a real-world perspective of caring for patients with kidney diseases in developing countries. The author also provided guidance for dealing with kidney diseases of these populations as a lower priority among other public health problems, including economic (...) (Kidney International 101, 6 (2022))
• 00:00
  Kidney health literacy and public health economics - Anthony M. Meyers Kidney Int
  The authors of the special report promoting World Kidney Day must be congratulated on their article dealing with “Kidney Health for All” (the International Society of Nephrology [ISN]/International Federation of Kidney Foundations [IFKF] slogan).1 This most interesting and thought-provoking (...) (Kidney International 101, 6 (2022))
• 00:00
  Renovascular hypertension secondary to massive iliopsoas hematoma - Ryunosuke Noda, Wei Han, Yugo Shibagaki, Masahiko Yazawa Kidney Int
  An 81-year-old woman with stage G3 chronic kidney disease status post left nephrectomy for upper tract urothelial carcinoma 20 years ago was admitted to our hospital for heart failure. She acutely developed right thigh pain, and contrast-enhanced computed tomography revealed an idiopathic (...) (Kidney International 101, 6 (2022))
• 00:00
  Cerebral venous sinus thrombosis in nephrotic syndrome - Xinyi Gao, Yueming Liu, Qiang He, Xiaogang Shen Kidney Int
  A 36-year-old woman presented to the emergency department with recurrent syncope. She was diagnosed with nephrotic syndrome 16 days previously. Since she refused a kidney biopsy, she had been empirically treated with oral prednisone. A noncontrast computed tomography scan of the brain showed a (...) (Kidney International 101, 6 (2022))
• 00:00
  A shining example of discolored dialysate - Kate Drummond, Matthew Davies Kidney Int
  A 56-year-old patient on home hemodialysis noticed a yellow discoloration to the effluent fluid in his dialyzer and tubing (Figure 1a) shortly after commencing dialysis. Dialysis was ceased and a dialysate sample collected. Medical history included autosomal dominant polycystic kidney disease, (...) (Kidney International 101, 6 (2022))
• 00:00
  The Case | Late allograft dysfunction with unexpected biopsy findings - Ibrahim Batal, Heather K. Morris Kidney Int
  A 63-year-old man with end-stage kidney disease secondary to atrophic right kidney and type 2 diabetes mellitus received a living-related kidney allograft from his sister. Induction therapy included thymoglobulin, and maintenance immunosuppression consisted of tacrolimus and mycophenolate (...) (Kidney International 101, 6 (2022))